TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37678575

Group type: EXPERIMENTAL
Intervention: HLH-related gene variants (LYST, PRF1, UNC13-D, STX11, STXBP2, RAB27A, XIAP, SAP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Presence of 1 variant allele
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Presence of 2-3 variant alleles
Number of subjects: 130
Study: 37678704

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 0
Study: 37678916

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37678915

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzalutamide-resistant cells
Number of subjects: 0
Study: 37678921

Group type: EXPERIMENTAL
Intervention: CPI613 (pharmacological inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: shRNA targeting PDHA1 and OGDH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of TCA cycle
Number of subjects: 0
Study: 37678943

Group type: EXPERIMENTAL
Intervention: vNOTES
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Abdominal Laparoscopy (CAL)
Number of subjects: 100
Study: 37678946

Group type: EXPERIMENTAL
Intervention: NeuroCARE intervention (six individual telehealth sessions over 12 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NeuroCARE intervention
Number of subjects: 120
Study: 37679247

Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography (CCTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive imaging modalities (IVUS, NIRS-IVUS, OCT)
Number of subjects: 0
Study: 37679276

Group type: EXPERIMENTAL
Intervention: gp145 C.6980 high dose (300 mcg), n = 25
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: gp145 C.6980 low dose (100 mcg), n = 15
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo/saline, n = 5
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: gp145 C.6980 (both doses), n = 40
Number of subjects: 45
Study: 37679434

Group type: EXPERIMENTAL
Intervention: Dasatinib (D) and Quercetin (Q)
Number of subjects: 5
Study: 37679536

Group type: EXPERIMENTAL
Intervention: Normal eGFR
Number of subjects: 6720

Group type: EXPERIMENTAL
Intervention: Mild CKD (eGFR=60-89 mL/min/1.73 m²)
Number of subjects: 6720
Study: 37679687

Group type: EXPERIMENTAL
Intervention: Particle-depleted diesel exhaust (PDDE)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diesel exhaust (DE)
Number of subjects: 13
Study: 37679712

Group type: EXPERIMENTAL
Intervention: Remote monitoring intervention for managing heart failure, including tracking patients' weight and diuretic adherence.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Lottery intervention as part of the remote monitoring program.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Electronic alerts as part of the remote monitoring intervention.
Number of subjects: 43
Study: 37679723

Group type: EXPERIMENTAL
Intervention: CGRP infusion (1.5 µg/min) over 20 min
Number of subjects: 34
Study: 37679760

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 11714

Group type: EXPERIMENTAL
Intervention: Diabetic patients with HPR phenotype
Number of subjects: 11714
Study: 37679771

Group type: EXPERIMENTAL
Intervention: Retrospective collection of EQ-5D-5L
Number of subjects: 676

Group type: COMPARATOR
Intervention: Standard prospective collection of EQ-5D-5L
Number of subjects: 676
Study: 37679845

Group type: EXPERIMENTAL
Intervention: Individual motivational interviewing sessions (online or in-person) with a trained interviewer plus educational materials (based on Canada's food guide and physical activity recommendations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational materials only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual motivational interviewing sessions (online or in-person) with a trained interviewer plus educational materials
Number of subjects: 0
Study: 37680714

Group type: EXPERIMENTAL
Intervention: Aficamten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37680774

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 37680791

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 639

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study: 37680795

Group type: EXPERIMENTAL
Intervention: Anti-cytokine treatment (tocilizumab in 53 patients, anakinra in 27 patients)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No anti-cytokine treatment (77 patients)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Anti-cytokine treatment
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: CMV reactivation
Number of subjects: 167
Study: 37680815

Group type: EXPERIMENTAL
Intervention: Partially threaded cannulated screw fixation (cancellous screws 6 mm)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fully threaded cannulated screw fixation (cancellous screws 6 mm)
Number of subjects: 82
Study: 37680892

Group type: EXPERIMENTAL
Intervention: Osilodrostat
Number of subjects: 60
Study: 37680942

Group type: EXPERIMENTAL
Intervention: CT017 CAR T cells at a dose of 250 × 10^6
Number of subjects: 6
Study: 37680953

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Dynamic MRD monitoring among ASCT
Number of subjects: 407
Study: 37681206

Group type: EXPERIMENTAL
Intervention: Integrated addiction team follow-up
Number of subjects: 611

Group type: COMPARATOR
Intervention: Control group (no addiction monitoring)
Number of subjects: 611
Study: 37681235

Group type: EXPERIMENTAL
Intervention: Washed microbiota transplantation (WMT)
Number of subjects: 54
Study: 37681568

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid plus docosahexaenoic acid (3.36 g/d) for 30 months
Number of subjects: 240

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 240
Study: 37681996

Group type: EXPERIMENTAL
Intervention: ICE-guided CBA (Group B)
Number of subjects: 1906

Group type: COMPARATOR
Intervention: Conventional CBA (Group A)
Number of subjects: 1906

Group type: COMPARATOR
Intervention: Non-ICE usage
Number of subjects: 1906
Study: 37682079

Group type: EXPERIMENTAL
Intervention: Self-hypnosis and self-care group intervention
Number of subjects: 95
Study: 37682253

Group type: EXPERIMENTAL
Intervention: Odor stimulation with breast milk (BM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study: 37682255

Group type: EXPERIMENTAL
Intervention: Whole-body Dual-energy X-ray absorptiometry (DXA) to assess skeletal muscle mass
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Handgrip dynamometer to measure muscle strength adjusted to body mass index
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anthropometric data collection including age, sex, body mass index, disease duration, and therapeutic management
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison to age and sex reference curves
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DXA scans for body composition including appendicular lean mass and skeletal muscle mass
Number of subjects: 30
Study: 37682297

Group type: EXPERIMENTAL
Intervention: Coach-guided video-conferencing expressive writing program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37682405

Group type: EXPERIMENTAL
Intervention: IND 75 µg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IND 150 µg
Number of subjects: 80
Study: 37682406

Group type: EXPERIMENTAL
Intervention: Rivermead Post-Concussion Symptoms Questionnaire (RPQ) - Dutch
Number of subjects: 2054

Group type: EXPERIMENTAL
Intervention: Rivermead Post-Concussion Symptoms Questionnaire (RPQ) - English
Number of subjects: 2054

Group type: EXPERIMENTAL
Intervention: Rivermead Post-Concussion Symptoms Questionnaire (RPQ) - Finnish
Number of subjects: 2054

Group type: EXPERIMENTAL
Intervention: Rivermead Post-Concussion Symptoms Questionnaire (RPQ) - Italian
Number of subjects: 2054

Group type: EXPERIMENTAL
Intervention: Rivermead Post-Concussion Symptoms Questionnaire (RPQ) - Norwegian
Number of subjects: 2054

Group type: EXPERIMENTAL
Intervention: Rivermead Post-Concussion Symptoms Questionnaire (RPQ) - Spanish
Number of subjects: 2054
Study: 37682573

Group type: EXPERIMENTAL
Intervention: Adaptive treatment with varenicline
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard treatment with varenicline
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Adaptive treatment with nicotine patches
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard treatment with nicotine patches
Number of subjects: 188
Study: 37682593

Group type: EXPERIMENTAL
Intervention: SyMon-SAYS intervention (16 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (8 weeks) followed by SyMon-SAYS intervention (8 weeks)
Number of subjects: 200
Study: 37682601

Group type: EXPERIMENTAL
Intervention: 68Ga-LNC1007 PET/CT
Number of subjects: 61

Group type: COMPARATOR
Intervention: 2-18F-FDG PET/CT
Number of subjects: 61

Group type: COMPARATOR
Intervention: 68Ga-FAPI-02 PET/CT
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 68Ga-LNC1007 PET
Number of subjects: 61
Study: 37682613

Group type: EXPERIMENTAL
Intervention: PETFL/MRI
Number of subjects: 34

Group type: COMPARATOR
Intervention: mpMRI
Number of subjects: 34

Group type: COMPARATOR
Intervention: PET/MRI PROMISE
Number of subjects: 34
Study: 37682791

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab (LR)
Number of subjects: 36
Study: 37682792

Group type: EXPERIMENTAL
Intervention: Zanubrutinib (160 mg twice daily)
Number of subjects: 68
Study: 37682839

Group type: EXPERIMENTAL
Intervention: High-intensity respiratory muscle training (60% of MIP and MEP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham training (0cmH2O)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-intensity respiratory muscle training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 34
Study: 37682841

Group type: EXPERIMENTAL
Intervention: Implicit learning intervention delivered by clinical teams, requiring therapists to change instructions and feedback during rehabilitation.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Implicit learning intervention
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Implementation of the implicit learning intervention
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Teams with a flexible culture
Number of subjects: 39
Study: 37682887

Group type: EXPERIMENTAL
Intervention: Antibiotic paste (CTZ)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Iodoform paste (Guedes-Pinto)
Number of subjects: 120
Study: 37682920

Group type: EXPERIMENTAL
Intervention: Ablative fractional CO2 laser treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 37682953

Group type: EXPERIMENTAL
Intervention: Abemaciclib pre-operatively for 4.5 days at twice daily dosing
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Abemaciclib therapy along with temozolomide
Number of subjects: 7
Study: 37682971

Group type: EXPERIMENTAL
Intervention: PopART intervention (arms A and B combined)
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Standard-of-care (arm C)
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: People living with HIV
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: HIV-negative individuals
Number of subjects: 1750
Study: 37683037

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (anti-PD-1), 2 doses
Number of subjects: 0
Study: 37683048

Group type: EXPERIMENTAL
Intervention: Low-profile double plating (one superiorly positioned VariAx 2.0mm and one anterior VariAx 2.4mm or 2.7mm plate)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Single plating (standard locally available implant)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Low-profile double plating
Number of subjects: 336

Group type: COMPARATOR
Intervention: Single plating
Number of subjects: 336
Study: 37683047

Group type: EXPERIMENTAL
Intervention: PlaySmart digital health game
Number of subjects: 532

Group type: COMPARATOR
Intervention: Time/attention control videogames
Number of subjects: 532
Study: 37683098

Group type: EXPERIMENTAL
Intervention: Long-Term Oxygen Therapy (LTOT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 37683122

Group type: EXPERIMENTAL
Intervention: Treatment strategies for pulmonary exacerbations in pediatric cystic fibrosis patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (if applicable)
Number of subjects: 0
Study: 37683234

Group type: EXPERIMENTAL
Intervention: Brexpiprazole Combination Therapy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study: 37683276

Group type: EXPERIMENTAL
Intervention: FF-10850
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FF-10850 + anti-PD-1 antibody
Number of subjects: 0
Study: 37683518

Group type: EXPERIMENTAL
Intervention: Metformin therapy plus standard care
Number of subjects: 5160

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 5160
Study: 37683686

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg once daily
Number of subjects: 681

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 681
Study: 37683799

Group type: EXPERIMENTAL
Intervention: 3 M True Definition Intraoral Scanner or 3 M Lava Chairside Oral Scanner
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 3D Wear Analysis (3DWA)-protocol with Geomagic Qualify
Number of subjects: 55

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study: 37683823

Group type: EXPERIMENTAL
Intervention: Cardiac transplantation
Number of subjects: 311
Study: 37684058

Group type: EXPERIMENTAL
Intervention: MISTIE intervention (minimally invasive surgery + recombinant tissue plasminogen activator (rt-PA))
Number of subjects: 506

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 506
Study: 37684252

Group type: EXPERIMENTAL
Intervention: Atezolizumab + nab-paclitaxel
Number of subjects: 52
Study: 37684267

Group type: EXPERIMENTAL
Intervention: Free-floating video laryngoscopy at the head of the manikin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional direct laryngoscopy in an ice-pick position
Number of subjects: 0
Study: 37684282

Group type: EXPERIMENTAL
Intervention: Permutation-based inference and a new ranked-based test statistic to identify sex-based epigenetic differences.
Number of subjects: 0
Study: 37684332

Group type: EXPERIMENTAL
Intervention: Nasal-spraying Bacillus spores (LiveSpo Navax) containing 5 billion of Bacillus subtilis and B. clausii spores in 5 mL.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal-spraying Bacillus spores (LiveSpo Navax)
Number of subjects: 0
Study: 37684373

Group type: EXPERIMENTAL
Intervention: TRC105 monotherapy (10 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bevacizumab+TRC105
Number of subjects: 22
Study: 37684426

Group type: EXPERIMENTAL
Intervention: Magnetic seeds (MS) placed into the target lymph node (TLN) before NACT
Number of subjects: 187
Study: 37684485

Group type: EXPERIMENTAL
Intervention: MMTT glucose AUC (180-min)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: MMTT glucose AUC (240-min)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: MMTT glucose iAUC (180-min)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: MMTT insulin AUC (180-min)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: MMTT insulin AUC (240-min)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: MMTT insulin iAUC (180-min)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Fasting OGTT glucose
Number of subjects: 168

Group type: COMPARATOR
Intervention: 120-min OGTT glucose
Number of subjects: 168

Group type: COMPARATOR
Intervention: OGTT insulin AUC and iAUC
Number of subjects: 168
Study: 37684526

Group type: EXPERIMENTAL
Intervention: Patients with Metabolic syndrome (MetS)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Patients without Metabolic syndrome (MetS)
Number of subjects: 229
Study: 37684597

Group type: EXPERIMENTAL
Intervention: Strength exercise
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (stationary cycling)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Strength exercise and Aerobic exercise
Number of subjects: 168
Study: 37684648

Group type: EXPERIMENTAL
Intervention: Retromuscular synthetic mesh during closure of loop ileostomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard suture closure of the abdominal wall
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retromuscular synthetic mesh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (suture closure)
Number of subjects: 0
Study: 37684682

Group type: EXPERIMENTAL
Intervention: Link work intervention (treatment as usual plus a link worker intervention) consisting of six sessions over 9 months.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Treatment as usual (control).
Number of subjects: 84
Study: 37684688

Group type: EXPERIMENTAL
Intervention: MDM with ADBoard (Arm A: MDM-AB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional MDM (Arm B: MDM-C)
Number of subjects: 0
Study: 37684697

Group type: EXPERIMENTAL
Intervention: EUS-CPN with bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: EUS-CPN without bupivacaine
Number of subjects: 0
Study: 37684728

Group type: EXPERIMENTAL
Intervention: Pre-CABG depression
Number of subjects: 161
Study: 37685793

Group type: EXPERIMENTAL
Intervention: Comprehensive transthoracic echocardiographic assessment including strain and myocardial work analysis of the left and right heart chambers within 48 hours of admission after coronary angiography.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory profile focusing on systemic inflammation captured during the first 24 hours upon admission.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Documentation of angioplasty details and non-culprit coronary lesions, and evaluation of coronary artery disease complexity using the SYNTAX score.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-month follow-up period for all patients recruited.
Number of subjects: 0
Study: 37685975

Group type: EXPERIMENTAL
Intervention: Citrus and pomegranate complex (CPC) 500 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 37685992

Group type: EXPERIMENTAL
Intervention: IMMAX (comprehensive immune age index)
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: EYOL (equivalent years of life)
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: IMMAX centiles
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Age gap (difference between EYOL and chronological age)
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 1605
Study: 37686032

Group type: EXPERIMENTAL
Intervention: Runcaciguat 1 mg/kg/bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Runcaciguat 3 mg/kg/bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Runcaciguat 10 mg/kg/bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Runcaciguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37686537

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant study concept
Number of subjects: 0
Study: 37688515

Group type: EXPERIMENTAL
Intervention: Kiosk
Number of subjects: 482

Group type: COMPARATOR
Intervention: Clinic
Number of subjects: 482

Group type: COMPARATOR
Intervention: Home
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: New hypertension diagnosis
Number of subjects: 482

Group type: COMPARATOR
Intervention: No new hypertension diagnosis
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 482
Study: 37689018

Group type: EXPERIMENTAL
Intervention: High-dose (60 Gy) IMRT with weekly cisplatin
Number of subjects: 88
Study: 37689244

Group type: EXPERIMENTAL
Intervention: Naïve FGF21
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: PF-05231023
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Naïve FGF21 and PF-05231023
Number of subjects: 442
Study: 37689323

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (a-tDCS) on left dorsolateral prefrontal cortex (l-DLPFC), n=34
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (a-tDCS) on primary motor cortex (M1), n=34
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (a-tDCS) on M1, n=34
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (s-tDCS) on l-DLPFC, n=17
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (s-tDCS) on M1, n=17
Number of subjects: 102
Study: 37689574

Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment
Number of subjects: 288
Study: 37689622

Group type: EXPERIMENTAL
Intervention: Painted playgrounds intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 51
Study: 37689733

Group type: EXPERIMENTAL
Intervention: Claudin 18.2 CAR T cell therapy
Number of subjects: 2
Study: 37689749

Group type: EXPERIMENTAL
Intervention: High-dose carboplatin-thiotepa-cyclophosphamide
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional chemotherapy (ddAC only or ddAC-capecitabine/decetaxel [CD] or ddAC-carboplatin/paclitaxel [CP])
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: ddAC/ddAC-CD
Number of subjects: 122

Group type: COMPARATOR
Intervention: ddAC-CP
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: High-dose alkylating chemotherapy
Number of subjects: 122
Study: 37689822

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing panel for 26 drugs
Number of subjects: 2612

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing panel for aripiprazole and serotonin or serotonin-norepinephrine reuptake inhibitors
Number of subjects: 2612
Study: 37689979

Group type: EXPERIMENTAL
Intervention: HER3-DXd 5.6 mg/kg once every 3 weeks
Number of subjects: 225